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a  b  s  t  r  a  c  t
Objectives:  We  conducted  an  open-label,  multicenter,  single-arm  study  to conﬁrm  the  efﬁcacy  and  safety
of  amrubicin  (AMR),  a topoisomerase  II  inhibitor,  for  treating  refractory  small-cell  lung  cancer  (SCLC).
Patients and  methods:  Patients  with  chemotherapy-refractory  SCLC  received  40  mg/m2 AMR  for  3  consec-
utive  days,  every  21  days.  The  primary  endpoint  was  the  overall  response  rate  (ORR)  and  the secondary
endpoints  were  progression-free  survival  (PFS),  overall  survival  (OS),  and  safety.
Results: Between  November  2009  and  February  2011,  82 patients  were enrolled.  Each patient  received  a
median  of  four treatment  cycles  (range,  1–22  cycles).  ORR was  32.9%  [P  <  0.0001  by  the  exact  binomial
test  for the  null  hypothesis  that  ORR ≤ 10%;  95% conﬁdence  interval  (CI), 22.9–44.2%].  The  median  PFS
and  OS periods  were  3.5  months  (95%  CI, 3.0–4.3  months)  and  8.9  months  (95%  CI,  7.6–11.3  months),efractory
mall-cell lung cancer
hase  II
respectively.  Signiﬁcant  differences  in  ORR  (21.4%  v 45.0%;  P =  0.034),  PFS  (median,  2.9  v 5.1  months;
P  =  0.0009),  and  OS  (median,  7.9 v 13.1  months;  P =  0.0128)  were  observed  between  patients  previously
treated  with  etoposide  and  others.  Neutropenia  was  the  most  common  grade  3  or 4  adverse  events
(93.9%),  and  febrile  neutropenia  developed  in  26.8%  patients.  No  treatment-related  death  occurred.
Conclusions: AMR  monotherapy  can be considered  an  effective  and  safe  treatment  option  for  refractory
SCLC.  Previous  chemotherapy  
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1. Introduction
Small-cell lung cancer (SCLC) is the most rapidly growing
lung cancer subtype and patient prognosis is extremely poor [1].
Although most SCLC patients respond to initial treatment, long-
Open access under CC BY-NC-SA licenseterm survival is low. Unfortunately, disease progression or relapse
occurs in almost all advanced-stage SCLC patients and in the major-
ity of early-stage SCLC patients [2–6]. Response to subsequent
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hemotherapy and the interval between cessation of initial therapy
nd disease progression [7,8].
Overall response rates (ORRs) of 21–38% and median overall
urvival (OS) of 6.9–11.7 months were reported in chemotherapy-
ensitive SCLC patients after treatment with topotecan, a
opoisomerase I inhibitor [8,9]. A previous randomized study
emonstrated similar efﬁcacy and improved tolerability of
opotecan compared with cyclophosphamide, doxorubicin, and
incristine [10]. Topotecan is also considered as a treatment option
or chemotherapy-refractory SCLC; however, low ORRs (0–11%)
nd OS (median, 4.7–5.4 months) have been reported [8,9,11]. Thus,
 standard chemotherapy for the treatment of refractory SCLC has
ot yet been established. However, effective treatment must be
eveloped to improve prognosis for SCLC patients.
Amrubicin (AMR), a fully synthetic 9-aminoanthracycline, is
etabolized in the body to the active metabolite amrubicinol,
hich has higher antitumor activity than AMR. Both AMR  and
mrubicinol, which are topoisomerase II inhibitors, exhibit antitu-
or activities against various human tumors in xenograft models
nd have shown no risk of typical anthracycline cardiotoxicity [12].
n subgroup analyses of small phase II studies, AMR  showed promis-
ng activity in patients with refractory SCLC with ORR of 17–50% and
edian OS of 5.3–10.3 months [9,13].
Accordingly, the results of previous studies indicated that AMR
ay be useful for treating refractory SCLC. Therefore, we conducted
his study to conﬁrm the efﬁcacy and safety of AMR, a topoiso-
erase II inhibitor, for treating refractory SCLC. A phase III trial
as preferred to evaluate the effectiveness of AMR  therapy; how-
ver, other than AMR  therapy, there was no promising treatment
nder development for refractory SCLC at that time. As second-
est evidence that was not from a randomized controlled trial,
e designed a nonrandomized single-arm conﬁrmatory study to
valuate whether AMR  therapy can be considered as a standard
reatment for refractory SCLC.
. Patients and methods
.1.  Study design
This  was an open-label, multicenter, single-arm conﬁrmatory
tudy involving 25 institutions in Japan. The study protocol was
pproved by the Japan Clinical Oncology Group (JCOG) Protocol
eview Committee and the institutional review board of each par-
icipating institution.
.2.  Eligibility criteria
Patients  were required to have histologically or cytologi-
ally documented SCLC, and were refractory to treatment with
ne or two previous chemotherapy regimens, at least one of
hich was platinum based. Refractory disease was deﬁned as
o response to previous chemotherapy, disease progression on
hemotherapy, or disease progression <90 days of completing
revious chemotherapy after conﬁrming a complete response
CR) or partial response (PR). Other inclusion criteria included
ge of 20–74 years, Eastern Cooperative Oncology Group per-
ormance status of 0–1, measurable disease, no history of
hemotherapy with AMR, no history of surgery for SCLC, no
horacic radiation therapy ≤4 weeks before registration, ade-
uate baseline organ function [leukocyte count ≥ 3000/mm3,
bsolute neutrophil count ≥ 1500/mm3, hemoglobin ≥ 9.0 g/dL,
latelet count ≥ 100,000/mm3, total bilirubin ≤ 2.0 mg/dL, aspar-
ate aminotransferase (AST) and alanine aminotransferase (ALT)
evels ≤ 100 IU/L, serum creatinine level ≤ 2.0 mg/dL, PaO2 under
oom air ≥ 60 mmHg, and electrocardiographic ﬁndings withinncer 84 (2014) 67–72
normal  range]. Written informed consent was obtained from
all patients. Patients were ineligible if they had active con-
comitant malignancy, massive pleural or pericardial effusion,
symptomatic brain metastasis, or severe comorbidities such as
active infections, uncontrolled hypertension, severe heart disease,
uncontrolled diabetes mellitus, bowel obstruction, psychiatric dis-
ease, severe emphysema, interstitial pneumonia, or pulmonary
ﬁbrosis. Patients having systemic steroid medication and pregnant
or breast feeding women were also excluded.
2.3. Treatment
Treatment was started within 1 week after enrollment in the
study. Patients received AMR  at 40 mg/m2/day for 3 consecutive
days, every 21 days. The treatment was repeated until disease
progression, intolerable toxicity, or patient refusal. The dose of
AMR was decreased to 35 mg/m2/day if any of the following were
observed during the previous course: leukocyte count <1000/mm3,
platelet count <20,000/mm3, grade 3 febrile neutropenia, or grade
3 nonhematological toxicity (except nausea, anorexia, weight loss,
creatinine, hyponatremia, hyperglycemia or alopecia). A second
dose reduction to 30 mg/m2/day was made in subsequent cycles
on the basis of the same criteria. In cases of grade 4 nonhematolog-
ical toxicity or continued toxicity that would have required a third
dose reduction, the protocol treatment was  terminated.
Patients received full supportive care as required, includ-
ing transfusion of blood products. The protocol speciﬁed that
granulocyte colony-stimulating factor (G-CSF) should be used in
accordance with the national health insurance coverage of Japan,
indications for G-CSF administration were as follows: (a) when
fever (in principal over 38 ◦C) was observed with a neutrophil
count of ≤1000/mm3; (b) when a neutrophil count of 500/mm3 was
observed; (c) during the previous course, if fever (in principal over
38 ◦C) with a neutrophil count of ≤1000/mm3 was observed, or if a
neutrophil count of 500/mm3 was  observed, then after completing
the same chemotherapy, if a neutrophil count of ≤1000/mm3 was
observed. There was no restriction for subsequent chemotherapy
after disease progression in this study.
2.4. Evaluation
The Response Evaluation Criteria in Solid Tumors guidelines
(ver. 1.0) was  used to evaluate tumor response [14]. Computed
tomography was  performed at baseline and at least every two
cycles. Conﬁrmation of a CR or PR was  required at least 4 weeks
after the ﬁrst documentation of a response. Independent review
of tumor response was  performed for patients with any extent of
tumor shrinkage. Three reviewers, including a diagnostic radiolo-
gist, were assigned as an independent review panel. Adverse events
were recorded and graded using the Common Terminology Crite-
ria for Adverse Events (ver. 3.0). Evaluation of cardiotoxicity was
performed as needed, as judged by the physician.
2.5. Study endpoints and statistical analysis
The primary endpoint in this study was ORR, which was cal-
culated as conﬁrmed response (CR + PR) according to independent
assessments. We  believe that tumor shrinkage is essential to
improve prognosis for refractory SCLC. Furthermore, previous stud-
ies for refractory SCLC showed large variations in survival times
[8,9,11,13]. Because ORR with slight variation was considered a
hard endpoint, we used ORR as the primary endpoint. As secondary
endpoints, we evaluated progression-free survival (PFS) and OS as
effectiveness endpoints and the incidence of an adverse event as a
safety endpoint. We  hypothesized that if the ORR of AMR  therapy
was high enough compared with that of topotecan therapy, AMR
































Response to amrubicin in the intent-to-treat population.





Not evaluable 2 2.4
Overall response rate (CR + PR) 27 32.9
95% CIa 22.9–44.2H. Murakami et al. / Lu
ould be considered as a standard treatment option. The sample size
as set as N = 80 to achieve a power of at least 80% with a one-sided
lpha of 0.05, and expected and threshold values for the primary
ndpoint of 20% and 10%, respectively. Survival was estimated using
he Kaplan–Meier method and subgroups were compared using the
og-rank test.
For  AMR  therapy to be considered as a standard option for
atients with refractory SCLC, its safety and survival should also
e equal or superior to those of topotecan therapy. According to
he results of previous topotecan studies [8,9,11], anticipated val-
es were 2.0–3.0 months for median PFS and 5.0–7.5 months for
edian OS, and a proportion of treatment-related deaths (≤5%) was
lso anticipated. The Fisher’s exact test was used to compare cat-
gorical data. All analyses were performed using SAS release 9.1
tatistical software (SAS Institute, Cary, NC, USA).
.  Results
.1. Patient characteristics
From  November 2009 to February 2011, a total of 82 patients
17 women and 65 men; median age, 66 years; age range, 44–74
ears) from 25 Japanese institutions were enrolled in this study.
ll 82 patients were eligible for analysis of the efﬁcacy and safety
f AMR. Patient characteristics are listed in Table 1. All 82 patients
eceived prior platinum-based chemotherapy, including pretreat-
ent with irinotecan-containing chemotherapy regimens (n = 47,
7.3%) and etoposide-containing chemotherapy regimens (n = 42,
1.2%). Thirteen of these patients had received thoracic radiation
herapy concurrently or sequentially with chemotherapy.Each patient received a median of four AMR  treatment cycles
range, 1–22 cycles), and 18 (22.0%) had a cumulative AMR  doses
xceeding 750 mg/m2. Reasons for off-protocol included disease
able 1












Disease extent at entry
Limited  disease 6 7.3
Extensive disease 76 92.7
No. of prior chemotherapy regimens
1 72 87.8
2 10 12.2
Prior chemotherapy regimen (multiple choices)
Cisplatin-containing 62 75.6
Carboplatin-containing 26 31.7




Response to prior chemotherapy
Complete  response 3 3.7
Partial response 58 70.7
Stable disease 4 4.9
Progressive disease 17 20.7
History of thoracic radiation therapy
No 69 84.1
Yes 13 15.9
bbreviation: ECOG, Eastern Cooperative Oncology Group.Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; CI, conﬁdence interval.
a Calculated by the exact method.
progression (n = 67), unacceptable toxicity (n = 8), and patient
refusal possibly related to adverse events (n = 7). AMR  dose reduc-
tion was  required in 31 patients (37.8%), and the dose was
decreased by two levels in seven patients (8.5%).
3.2. Response
Independent reviews of tumor response were performed for 39
patients with any extent of tumor shrinkage. Among the total study
population, CR was achieved in two patients (2.4%), PR in 25 (30.5%),
stable disease (SD) in 37 (45.1%) after two courses, and progressive
disease (PD) in 16 (19.5%). The response was not evaluable in two
patients (2.4%) as a result of early termination of the treatment
protocol. One patient refused further treatment after one cycle of
AMR  therapy, and the other terminated therapy because of poor
performance status. Thus, for AMR  therapy, an ORR  of 32.9% was
observed in our study population (P < 0.0001 by the exact binomial
test for the null hypothesis that ORR ≤10%; 95% CI, 22.9–44.2%)
(Table 2).In  a subset analysis of response to AMR, ORR was lower in
patients treated with etoposide than in others (21.4% v 45.0%,
respectively; P = 0.034) (Table 3). No remarkable difference in
ORR was observed according to demographic characteristics [age,
Table 3
Subset analysis of response to amrubicin.
Characteristics Number of patients Response rate (%) P
Age (years)
44–70 61 32.8 1.00
≥71 21 33.3
Gender
Female  17 47.1 0.25
Male 65 29.2
ECOG  performance status
0 34 35.3 0.81
1 48 31.3
Disease  extent at entry
Limited  disease 6 16.7 0.66
Extensive disease 76 34.2
No.  of prior chemotherapy regimens
1 72 36.1 0.15
2 10 10.0
Prior  treatment with irinotecan
No 35 25.7 0.25
Yes 47 38.3
Prior  treatment with etoposide
No 40 45.0 0.034
Yes 42 21.4
Response  to prior chemotherapy
CR/PR  61 36.1 0.42
SD/PD 21 23.8
History  of thoracic radiation therapy
No 69 33.3 1.00
Yes 13 30.8
Abbreviations: ECOG, Eastern Cooperative Oncology Group; CR, complete response;
PR, partial response; SD, stable disease; PD progressive disease.
































Fig. 2. (A) Progression-free survival and (B) overall survival in patients previously
treated with etoposide (n = 42) and those not treated with etoposide (n = 40).
Table 4
Grade 3 or 4 adverse events in patients treated with amrubicin (N = 82) (CTCAE v3.0).
Adverse event Grade 3 Grade 4 ≥Grade 3
n % n % n %
Leukopenia 48 58.5 22 26.8 70 85.4
Anemia 19 23.2 2 2.4 21 25.6
Thrombocytopenia 12 14.6 5 6.1 17 20.7
Neutropenia 18 22.0 59 72.0 77 93.9
Febrile neutropenia 22 26.8 0 0.0 22 26.8
Hyperglycemia 11 16.4 0 0.0 11 16.4
Hyponatremia 9 11.0 4 4.9 13 15.9
Infection 5 6.1 1 1.2 6 7.3
Dyspnea 3 3.7 1 1.2 4 4.9
Elevated ALT level 4 4.9 0 0.0 4 4.9
Elevated AST level 3 3.7 0 0.0 3 3.7
Anorexia 3 3.7 0 0.0 3 3.7
Pneumonitis 2 2.4 1 1.2 3 3.7
Fatigue 1 1.2 0 0.0 1 1.2
Weight loss 1 1.2 0 0.0 1 1.2
Nausea 1 1.2 0 0.0 1 1.2
Sensory neuropathy 1 1.2 0 0.0 1 1.2ig. 1. (A) Progression-free survival and (B) overall survival of patients treated with
mrubicin (n = 82).
ender, performance status, disease extent at entry, number of
rior chemotherapy regimens, prior treatment with irinotecan,
esponse to prior chemotherapy (CR/PR v SD/PD), or history of tho-
acic radiation therapy].
.3.  Survival
At  the cutoff date for data collection, the median follow-up time
as 8.8 months in all registered patients (range, 1.5–23.8 months).
f the 82 patients, 81 (98.8%) were observed until disease progres-
ion and 66 (80.5%) until death. The median PFS for all 82 patients
as 3.5 months (95% CI, 3.0–4.3 months) and the PFS at 6 months
as 23.2% (95% CI, 14.7–32.7%; Fig. 1A). The median OS for all 82
atients was 8.9 months (95% CI, 7.6–11.3 months) and the 1-year
urvival was 35.7% (95% CI, 25.4–46.1%; Fig. 1B).
PFS was shorter in patients previously treated with etoposide
han in others (median, 2.9 v 5.1 months; hazard ratio, 2.11; 95%
I, 1.35–3.30; P = 0.0009; Fig. 2A), as was OS (median, 7.9 v 13.1
onths; hazard ratio, 1.86; 95% CI, 1.13–3.06; P = 0.0128; Fig. 2B).
.4. Safety
The most common adverse events were hematological tox-
cities, including grade-3 or -4 neutropenia (93.9%), leukopenia
85.4%), anemia (25.6%), and thrombocytopenia (20.7%; Table 4).
rade-3 febrile neutropenia developed in 22 patients (26.8%). Non-
ematological toxicities were generally mild and no evidence of
ardiotoxicity of AMR  was found in this study (Table 4). Pneumoni-
is was observed in nine patients (grade 4, n = 1; grade 3, n = 2; grade
, n = 3; and grade 1, n = 3), and seven (grade 4, n = 1; grade 3, n = 2;
rade 2, n = 2; and grade 1, n = 2) discontinued treatment because
f unacceptable toxicity levels. The incidence rate of pneumonitis
as higher in patients with history of thoracic radiation therapy
han in others (38.5% v 5.8%, respectively), but one grade 4 pneu-
onitis case was observed in a patient without a history of thoracic
adiation therapy.Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; CTCAE,
Common Terminology Criteria for Adverse Events.
G-CSF was administered to 51 (62.2%) patients and blood trans-
fusions were necessary in 9 (11.0%). No treatment-related death
was observed in this study.
4.  Discussion
This single-arm conﬁrmatory study was conducted to conﬁrm
the efﬁcacy and safety of AMR  in patients with refractory SCLC. In
the present study, the primary endpoint was  the ORR, which was
32.9%. This data supported the result that the ORR of AMR  therapy
was signiﬁcantly better than that of topotecan therapy, in accor-
dance with that previously reported in a randomized phase II study
by Inoue et al. [9]. A possible limitation of this study is related to
its design, which was not a randomized phase III study, but rather
a nonrandomized single-arm conﬁrmatory study. Although there































































tH. Murakami et al. / Lu
as sufﬁciently higher than that for topotecan therapy in previ-
us studies [8,11]. The secondary endpoints, PFS and OS, were also
avorable, and no treatment-related deaths occurred in this study.
n the basis of these results, we conclude that AMR monotherapy
s suitable as an effective and safe treatment option for refractory
CLC.
Jotte et al. [15] reported the results of a randomized phase III
rial of AMR  versus topotecan as second-line treatment for SCLC.
he study randomized 637 patients in a 2:1 ratio for treatment
ith AMR (n = 424) or topotecan (n = 213). Treatment with AMR  and
opotecan showed similar OS periods (median, 7.5 v 7.8 months;
azard ratio for death, 0.880; 95% CI, 0.733–1.057; P = 0.17); how-
ver, higher ORRs (31.1% v 16.9%; P = 0.0001) and PFS periods
median, 4.1 v 3.5 months; hazard ratio for death or disease pro-
ression, 0.802; 95% CI, 0.667–0.965; P = 0.0182) were found with
MR therapy, and toxicity levels were more acceptable than those
ith topotecan therapy. Furthermore, in a subset analysis of 295
atients with refractory SCLC, AMR  therapy demonstrated a mod-
st improvement in OS (median, 6.2 v 5.7 months; hazard ratio for
eath, 0.766; 95% CI, 0.589–0.997; P = 0.0469). These results sup-
ort our assertion that AMR  monotherapy is a reasonable treatment
ption for patients with refractory SCLC.
In this study, a subgroup analysis revealed that prior treat-
ent with etoposide, a topoisomerase II inhibitor, was  associated
ith a poorer response to AMR  and poor survival. Ettinger et al.
16] reported the results of a phase II study of AMR  as a second-
ine therapy for patients with platinum-refractory SCLC. In total,
5 American and European patients were enrolled, of whom, 67
89.3%) were pretreated with a chemotherapy regimen including
toposide. The conﬁrmed ORR of AMR  therapy was  21.3% (95% CI,
2.7–32.3%) and the median PFS was 3.2 months (95% CI, 2.4–4.0
onths). These efﬁcacy data are similar to those of the patients
reviously treated with etoposide in the present Japanese study.
herefore, previous chemotherapy with etoposide, but not eth-
ic differences, may  have inﬂuenced the efﬁcacy of AMR  therapy.
reclinical studies [17–20] have suggested that treatment with
opoisomerase I inhibitors results in downregulation of the topo-
somerase I target and reciprocal upregulation of topoisomerase
I, thereby causing hypersensitivity to topoisomerase II inhibitors.
onversely, treatment with topoisomerase II inhibitors results in
ownregulation of topoisomerase II and upregulation of topoiso-
erase I. These results may  explain why prior treatment with
toposide was associated with a lower response to AMR  therapy
n the present study.
Although  etoposide plus cisplatin (EP) is considered the
tandard ﬁrst-line chemotherapy for patients with extensive-stage
CLC in Western countries, irinotecan, a topoisomerase I inhibitor,
lus cisplatin (IP) is generally used for Japanese patients, which is
ased on the results of a previous phase III study comparing IP with
P for extensive-stage SCLC (JCOG9511) [2]. AMR  may  also play an
mportant role in the treatment of refractory SCLC, especially for
atients previously treated with IP. In a recent Japanese phase III
tudy comparing AMR plus cisplatin (AP) with IP for the treatment
f extensive-stage SCLC (JCOG0509) [21], similar PFS periods were
ound for AP and IP (median, 5.1 v 5.7 months), but AP was  inferior
o IP in terms of OS (median, 15.3 v 18.0 months). Over 90% patients
n both groups received subsequent chemotherapy. The most com-
only administered drugs after the termination of treatment were
opotecan in the AP group and AMR  in the IP group. Subsequent
hemotherapy with AMR  may  have contributed to the longer OS
eriod in the IP group.
The  most common severe toxicity associated with AMR  ther-py in the present study was myelosuppression in the form of
eutropenia. No treatment-related death was observed, which was
robably because of the reasonable protocol-speciﬁed dose reduc-
ions and/or treatment delays. However, patients experiencedncer 84 (2014) 67–72 71
febrile  neutropenia more frequently in the present study (26.8%)
than in previous studies (5.0–13.8%) [9,13,16]. According to the
guidelines of the American Society of Clinical Oncology, prophy-
lactic G-CSF use is clinically effective when the risk of febrile
neutropenia is 20% [22]. To decrease the incidence of febrile
neutropenia in patients treated with AMR  for refractory SCLC,
aggressive treatment of myelosuppression, including prophylactic
G-CSF use, should be considered. Nonhematological toxicity was
generally mild, but the treatment was terminated in eight patients
(9.8%) because of unacceptable toxicity levels, including pneumoni-
tis in seven. Although no death was associated with pneumonitis
in the present study, careful monitoring for the development of
pneumonitis is necessary. Similar to previous studies [9,13,16], no
evidence of anthracycline-induced cardiotoxicity was found.
In  conclusion, AMR  monotherapy for refractory SCLC showed a
favorable tumor response, prolonged survival, and acceptable tox-
icity, especially in patients not previously treated with etoposide.
Therefore, AMR  monotherapy presents a standard treatment option
for refractory SCLC.
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